Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chhajed, P. N.
Right arrow Articles by Brutsche, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chhajed, P. N.
Right arrow Articles by Brutsche, M. H.
(Chest. 2006;130:1803-1807.)
© 2006 American College of Chest Physicians

Outcome of Treated Advanced Non-small Cell Lung Cancer With and Without Central Airway Obstruction*

Prashant N. Chhajed, MD, FCCP; Florent Baty, PhD; Miklos Pless, MD; Stephanie Somandin; Michael Tamm, MD and Martin H. Brutsche, MD, FCCP

* From Pulmonary Medicine (Drs. Chhajed, Baty, Tamm, Brutsche, and Ms. Somandin) and Oncology (Dr. Pless), University Hospital Basel, Basel, Switzerland.

Correspondence to: Prashant N. Chhajed, MD, FCCP, Pulmonary Medicine, University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland; e-mail: pchhajed{at}uhbs.ch

Abstract

Objective: In patients with advanced non-small cell lung cancer (NSCLC) treated with chemotherapy, we compared survival in patients with treated central airway obstruction to those who did not have central airway obstruction.

Methods: One hundred forty-four patients with advanced and inoperable NSCLC were included. These consisted of 52 consecutive patients treated with therapeutic bronchoscopy plus chemotherapy with or without radiotherapy (group A) and 92 consecutive patients who did not have central airway obstruction treated with chemotherapy alone (group B). Chemotherapy consisted of cisplatin or carboplatin, and one third-generation chemotherapy agent.

Results: There was no significant difference in the survival of patients with and without central airway obstruction (p = 0.395). There was no influence of the histologic subtype on survival in both groups combined and also in each group separately. Median survival in patients belonging to group A was 8.4 months and those in group B was 8.2 months; 3-, 6-, and 12-month survival rates in patients in group A were 90%, 71%, and 40%, respectively, and those in group B were 82%, 63%, and 34%.

Conclusion: Patients having advanced NSCLC with locally treated malignant central airway obstruction in combination with chemotherapy do not have a worse survival compared to those with advanced NSCLC without central airway obstruction. Therapeutic bronchoscopy should be offered to patients with NSCLC and central airway obstruction.

Key Words: bronchoscopy • chemotherapy • lung cancer






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Chest Physicians.